Tracking Drug‐Induced Epithelial–Mesenchymal Transition in Breast Cancer by a Microfluidic Surface‐Enhanced Raman Spectroscopy Immunoassay
| Autor: | Lynlee L. Lin, Andreas Möller, Alain Wuethrich, Matt Trau, Karthik Balaji Shanmugasundaram, Jing Wang, Belinda Yeo, Zhen Zhang |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Epithelial-Mesenchymal Transition
Microfluidics Breast Neoplasms 02 engineering and technology Spectrum Analysis Raman 010402 general chemistry 01 natural sciences Metastasis Biomaterials Breast cancer Cell Line Tumor Sense (molecular biology) medicine Humans General Materials Science Epithelial–mesenchymal transition Immunoassay medicine.diagnostic_test Chemistry Mesenchymal stem cell Cancer General Chemistry Surface-enhanced Raman spectroscopy Cadherins 021001 nanoscience & nanotechnology medicine.disease 0104 chemical sciences 3. Good health Pharmaceutical Preparations Cancer research 0210 nano-technology Biotechnology |
| Zdroj: | Small. 16:1905614 |
| ISSN: | 1613-6829 1613-6810 |
| DOI: | 10.1002/smll.201905614 |
| Popis: | Epithelial–mesenchymal transition (EMT) is a primary mechanism for cancer metastasis. Detecting the activation of EMT can potentially convey signs of metastasis to guide treatment management and improve patient survival. One of the classic signatures of EMT is characterized by dynamic changes in cellular expression levels of E-cadherin and N-cadherin, whose soluble active fragments have recently been reported to be biomarkers for cancer diagnosis and prognosis. Herein, a microfluidic immunoassay (termed “SERS immunoassay”) based on sensitive and simultaneous detection of soluble E-cadherin (sE-cadherin) and soluble N-cadherin (sN-cadherin) for EMT monitoring in patients' plasma is presented. The SERS immunoassay integrates in situ nanomixing and surface-enhanced Raman scattering readout to enable accurate detection of sE-cadherin and sN-cadherin from as low as 10 cells mL. This assay enables tracking of a concurrent decrease in sE-cadherin and increase in sN-cadherin in breast cancer cells undergoing drug-induced mesenchymal transformation. The clinical potential of the SERS immunoassay is further demonstrated by successful detection of sE-cadherin and sN-cadherin in metastatic stage IV breast cancer patient plasma samples. The SERS immunoassay can potentially sense the activation of EMT to provide early indications of cancer invasions or metastasis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text